Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means - 2‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- 3Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- 4The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- 5Vote in favor of your Number one method for commending a birthday
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- Americans generally like wolves − except when we’re reminded of our politics
- Two UN peacekeepers killed in explosion in Lebanon
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- The Drone Video of the Year is stunning – you've not seen Namibia like this
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 18
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
